Leaderboard
Anzeige
medline.ch
En
|
De
Impressum
No articles selected!
View Cart
You are here:
Oncology
»
Gynecologic Neoplasms
06. August 2026
Search
medline.ch
Gynecologic Neoplasms
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
Musculoskeletal System
Blood
Endocrine System
Gynecologic Neoplasms
Skin
Gastrointestinal
ORL
Respiratory Tract
Urologic Neoplasms
CNS
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Anzeige
Zoom:
Page 1 of 16663
Articles 1 - 20 / 333256
Integrative analysis of TCGA data identifies hsa-miR-200a as a breast cancer-associated microRNA biomarker with exploratory serum validation.
Genes Genomics
Park K, Kim EY, Lee EJ, Nam H, Park HW, Lee EH, Kim H, Lee KE, Jeon D, Kim J.
PMID: 42560646 [PubMed - as supplied by publisher]
A novel tRNA-derived fragment, tRF-19-79MP9PJZ, promotes uterine corpus endometrial carcinoma progression by targeting DSC3.
Hum Cell
Jiang H, Jiang T, Shen Y, Jiang H, Yuan Q.
PMID: 42560623 [PubMed - indexed for MEDLINE]
Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study.
Clin Transl Oncol
Ferro A, Campora M, Eccher C, Lorenzi M, Biondi R, Caldara A, Cantarelli S, Campregher M, Carbone G, De Lisi D, Dipasquale M, Lazzeri S, Monteverdi S, Armatura G, De Rose F, Gori S, Valentini M, Caffo O.
PMID: 42560581 [PubMed - as supplied by publisher]
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities.
Target Oncol
Chinea L, Hauer C, Pal K, Chang HL, Chan IS.
PMID: 42560566 [PubMed - as supplied by publisher]
P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2- Metastatic Breast Cancer in the USA-A Vodcast.
Target Oncol
Rugo HS, Ryan JC.
PMID: 42560565 [PubMed - as supplied by publisher]
Optimising screening intervals and BI-RADS management pathways in ultrasound-based breast cancer screening: real-world evidence from Shenzhen (2018-2023).
Breast Cancer Res Treat
Sun W, Li H, Zhao X, Hu S, Qi H, Jin S, Zhang W, Zhao F.
PMID: 42560548 [PubMed - indexed for MEDLINE]
Commissioning and clinical positioning assessment of a novel surface-guided radiation therapy (SGRT) system at a C-Arm linear accelerator.
J Appl Clin Med Phys
Looe HK, Bartner NFH, Poppe B, Willborn KC.
PMID: 42560082 [PubMed - indexed for MEDLINE]
Emergency Gynecologic Surgery Outcomes During Working and Off-Hours.
JSLS
Karabulut A, Kantarc, Da, Sezen D, At, , Özer M, Özeren M.
PMID: 42559505 [PubMed - indexed for MEDLINE]
Trop2-targeted PET/CT imaging with (68)Ga-MY6349 improves diagnostic accuracy and influences clinical management in breast cancer.
Theranostics
Yu L, Zhao L, Zeng R, Su Y, Wu Z, Yu S, Li Y, Fu H, Guo W, Sun Y, Gao H, Sun L, Wu H, Ye F, Wang F, Chen H.
PMID: 42559486 [PubMed - indexed for MEDLINE]
Liquid biopsy in breast cancer: current biomarker platforms and clinical applications.
Explor Target Antitumor Ther
Podder PS, Bhadra D, Martinelli C, Cortellino S, Giordano A, Cinti S.
PMID: 42558869 [PubMed]
Informing mobile health strategies: Study of mobile phone ownership among rural women for breast cancer control in Ghana.
Digit Health
Boamah Mensah AB, Mensah KB, Agbeko AE, Mohammed A, Okyere J, Dodd C, Horvath K, Virnig B, Clegg-Lamptey JN, Kulasingam S.
PMID: 42558772 [PubMed]
Cell competition within breast tumor microenvironment: emerging role of cancer stem cells and immune cells in tumor progression and therapeutic implications.
Front Oncol
Pal E, Chakraborty S, Guha A.
PMID: 42558596 [PubMed]
Establishment and evaluation of novel prognostic biomarkers based on systemic coagulation-inflammation index and related genes in breast cancer.
Front Immunol
Li F, Gao T, Xia J, Wang J, Su Q, Chen Y, Ba Y, Jia S, Li Z, Wang Y, Xiao M.
PMID: 42558555 [PubMed - indexed for MEDLINE]
Implementing a perioperative weight management program for ovarian cancer patients undergoing ultra-radical cytoreduction: a quality improvement initiative.
Front Oncol
Ying C, Cao W, Fan T, Fu L.
PMID: 42558467 [PubMed]
Knowledge, attitudes, and practice in breast cancer early detection: evidence from a nationally stratified study of healthcare providers in Jordan.
Front Public Health
ALSalamat H, Qtaishat E, Jardaneh D, Al-Hadid M, Al-Ajlouni R.
PMID: 42558454 [PubMed - indexed for MEDLINE]
Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy.
Front Oncol
D'Amato M, Morritti M, Morelli F, Ciuffreda L, Castelvetere M, Mangiacotti FP, Pasculli B, Parrella P.
PMID: 42558411 [PubMed]
Coagulation dysfunction as an independent predictor of early pregnancy loss in women with polycystic ovary syndrome: a machine learning-based retrospective cohort study.
Front Endocrinol (Lausanne)
Yu S, Wang Z, Yin X, Zhang Q.
PMID: 42558371 [PubMed - indexed for MEDLINE]
Logistic regression-based model for differential diagnosis between plasma cell mastitis and non-mass type breast cancer.
Front Oncol
Gao Q, Li J, Xia C.
PMID: 42558310 [PubMed]
Case Report: From standard therapy refusal to rare metastases: a case of untreated HER2-positive breast cancer progressing to brain and thyroid metastases after seven years of follow-up during which the patient received only Chinese herbal medicine.
Front Oncol
Yu Q, Zhang J, Li H, He K.
PMID: 42558245 [PubMed]
Decoding Intratumoral Heterogeneity in Breast Cancer: The Evolution From Radiomics to Topological Quantification for Predicting Lymphovascular Invasion.
Cancer Control
Zuo Z, Li Y, Zeng Y.
PMID: 42557854 [PubMed - indexed for MEDLINE]
Articles 1 - 20 / 333256
Page 1 of 16663
Rect Bottom
Anzeige
Adserver Footer
Time frame
--unlimited--
1 Week
1 Month
3 Months
6 Months
1 Year
2 Years
3 Years
5 Years
10 Years
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Privacy Policy